PL372900A1 - Leczenie zespołu zaburzeń metabolicznych - Google Patents

Leczenie zespołu zaburzeń metabolicznych

Info

Publication number
PL372900A1
PL372900A1 PL03372900A PL37290003A PL372900A1 PL 372900 A1 PL372900 A1 PL 372900A1 PL 03372900 A PL03372900 A PL 03372900A PL 37290003 A PL37290003 A PL 37290003A PL 372900 A1 PL372900 A1 PL 372900A1
Authority
PL
Poland
Prior art keywords
treatment
metabolic syndrome
metabolic
syndrome
Prior art date
Application number
PL03372900A
Other languages
English (en)
Inventor
Bernhard Saller
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of PL372900A1 publication Critical patent/PL372900A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03372900A 2002-04-26 2003-04-24 Leczenie zespołu zaburzeń metabolicznych PL372900A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome

Publications (1)

Publication Number Publication Date
PL372900A1 true PL372900A1 (pl) 2005-08-08

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372900A PL372900A1 (pl) 2002-04-26 2003-04-24 Leczenie zespołu zaburzeń metabolicznych

Country Status (11)

Country Link
EP (1) EP1499357A1 (pl)
JP (1) JP2005523915A (pl)
KR (1) KR20040101545A (pl)
CN (1) CN1646167A (pl)
AU (1) AU2003227683A1 (pl)
BR (1) BR0309375A (pl)
CA (1) CA2483005A1 (pl)
IL (1) IL164670A0 (pl)
MX (1) MXPA04010544A (pl)
PL (1) PL372900A1 (pl)
WO (1) WO2003090784A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2406493C1 (ru) * 2009-05-27 2010-12-20 Илья Николаевич Медведев Способ нормализации активности секреции аденозиндифосфата и аденозинтрифосфата тромбоцитами у больных с артериальной гипертонией и нарушением толерантности к глюкозе
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides

Also Published As

Publication number Publication date
JP2005523915A (ja) 2005-08-11
KR20040101545A (ko) 2004-12-02
IL164670A0 (en) 2005-12-18
EP1499357A1 (en) 2005-01-26
AU2003227683A1 (en) 2003-11-10
CN1646167A (zh) 2005-07-27
MXPA04010544A (es) 2005-08-16
BR0309375A (pt) 2005-03-29
CA2483005A1 (en) 2003-11-06
WO2003090784A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
IL218909A0 (en) Treatment of diabetes
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL164266A0 (en) Treatment of gastroparesis
GB0201674D0 (en) Medical treatment
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
GB0213869D0 (en) The treatment of pain
GB0223854D0 (en) Therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
GB0210741D0 (en) Methods of therapy
GB0221157D0 (en) Novel treatment
IL164951A0 (en) The treatment of pain with lfendropil
PL372900A1 (pl) Leczenie zespołu zaburzeń metabolicznych
GB0217493D0 (en) Novel methods of treatment
EP1573063A4 (en) TREATMENT OF LIVER DISEASES
GB0221712D0 (en) Methods of treatment
GB0212821D0 (en) Eyewash
GB0203328D0 (en) Substrate treatment
GB2392617A8 (en) Surface treatment of SARS-infected lungs
GB0329357D0 (en) Treatment of materials
PL356853A1 (pl) Zastosowanie bakteriofagów
GB0208783D0 (en) Methods of treatment
GB0223254D0 (en) Methods of treatment
GB0207139D0 (en) Novel therapeutic treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)